Novo Nordisk (0QIU) Share Forecast & Price Target

Compare

79 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QIU Analyst Ratings

Hold

1 Buy

10 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr300.92

▲(28.56% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr300.92 with a high forecast of kr380.00 and a low forecast of kr250.00. The average price target represents a 28.56% change from the last price of kr234.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"249":"kr249","624":"kr624","342.75":"kr342.8","436.5":"kr436.5","530.25":"kr530.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr300.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr250.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[249,342.75,436.5,530.25,624],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373.05,373.5846153846154,374.1192307692308,374.6538461538462,375.1884615384615,375.7230769230769,376.2576923076923,376.7923076923077,377.3269230769231,377.8615384615385,378.3961538461538,378.9307692307692,379.4653846153846,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373.05,367.5015384615385,361.95307692307694,356.4046153846154,350.85615384615386,345.3076923076923,339.7592307692308,334.21076923076924,328.6623076923077,323.11384615384617,317.56538461538463,312.0169230769231,306.46846153846155,{"y":300.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373.05,363.5846153846154,354.1192307692308,344.6538461538462,335.1884615384615,325.7230769230769,316.2576923076923,306.7923076923077,297.3269230769231,287.86153846153843,278.3961538461539,268.9307692307692,259.4653846153846,{"y":250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":594.699,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623.088,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475.892,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.716,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.509,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.775,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.159,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.591,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.642,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.273,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.589,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr380.00

Average Price Targetkr300.92

Lowest Price Targetkr250.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon CFA

Barclays

kr270

Hold

15.35%

Upside

Reiterated

03/03/26

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr400→kr260

Hold

11.08%

Upside

Downgraded

03/02/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Goldman Sachs

Richard Vosser

J.P. Morgan

kr350→kr250

Hold

6.81%

Upside

Downgraded

02/24/26

Novo Nordisk downgraded to Neutral from Overweight at JPMorganNovo Nordisk downgraded to Neutral from Overweight at JPMorgan

David Evans

Kepler Capital

kr400→kr280

Hold

19.62%

Upside

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at Kepler CheuvreuxNovo Nordisk downgraded to Hold from Buy at Kepler Cheuvreux

Graham Parry

Citi

kr340→kr309

Hold

32.01%

Upside

Reiterated

02/24/26

Novo Nordisk price target lowered to DKK 309 from DKK 340 at CitiNovo Nordisk price target lowered to DKK 309 from DKK 340 at Citi

Matthew Weston

UBS

kr332

Hold

41.84%

Upside

Reiterated

02/23/26

UBS Remains a Hold on Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

kr400→kr275

Hold

17.49%

Upside

Downgraded

02/23/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Deutsche Bank

Michael Leuchten

Jefferies

kr275

Hold

17.49%

Upside

Reiterated

02/23/26

Jefferies Keeps Their Hold Rating on Novo Nordisk (0QIU)

Kerry Holford

Berenberg Bank

kr415→kr360

Buy

53.80%

Upside

Reiterated

02/12/26

Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

kr400→kr350

Hold

49.53%

Upside

Reiterated

02/05/26

Novo Nordisk price target lowered to DKK 350 from DKK 400 at BofANovo Nordisk price target lowered to DKK 350 from DKK 400 at BofA

Thibault Boutherin

Morgan Stanley

kr270

Sell

15.35%

Upside

Reiterated

02/04/26

Morgan Stanley Sticks to Its Sell Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr380

Hold

62.34%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and HCA Healthcare (NYSE: HCA)

Rajesh Kumar

HSBC

kr300

Hold

28.17%

Upside

Downgraded

11/24/25

Novo Nordisk downgraded to Hold from Buy at HSBCNovo Nordisk downgraded to Hold from Buy at HSBC

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

11/24/25

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

kr540

Buy

130.70%

Upside

Reiterated

11/04/25

Bernstein Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon CFA

Barclays

kr270

Hold

15.35%

Upside

Reiterated

03/03/26

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr400→kr260

Hold

11.08%

Upside

Downgraded

03/02/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Goldman Sachs

Richard Vosser

J.P. Morgan

kr350→kr250

Hold

6.81%

Upside

Downgraded

02/24/26

Novo Nordisk downgraded to Neutral from Overweight at JPMorganNovo Nordisk downgraded to Neutral from Overweight at JPMorgan

David Evans

Kepler Capital

kr400→kr280

Hold

19.62%

Upside

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at Kepler CheuvreuxNovo Nordisk downgraded to Hold from Buy at Kepler Cheuvreux

Graham Parry

Citi

kr340→kr309

Hold

32.01%

Upside

Reiterated

02/24/26

Novo Nordisk price target lowered to DKK 309 from DKK 340 at CitiNovo Nordisk price target lowered to DKK 309 from DKK 340 at Citi

Matthew Weston

UBS

kr332

Hold

41.84%

Upside

Reiterated

02/23/26

UBS Remains a Hold on Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

kr400→kr275

Hold

17.49%

Upside

Downgraded

02/23/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Deutsche Bank

Michael Leuchten

Jefferies

kr275

Hold

17.49%

Upside

Reiterated

02/23/26

Jefferies Keeps Their Hold Rating on Novo Nordisk (0QIU)

Kerry Holford

Berenberg Bank

kr415→kr360

Buy

53.80%

Upside

Reiterated

02/12/26

Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

kr400→kr350

Hold

49.53%

Upside

Reiterated

02/05/26

Novo Nordisk price target lowered to DKK 350 from DKK 400 at BofANovo Nordisk price target lowered to DKK 350 from DKK 400 at BofA

Thibault Boutherin

Morgan Stanley

kr270

Sell

15.35%

Upside

Reiterated

02/04/26

Morgan Stanley Sticks to Its Sell Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr380

Hold

62.34%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and HCA Healthcare (NYSE: HCA)

Rajesh Kumar

HSBC

kr300

Hold

28.17%

Upside

Downgraded

11/24/25

Novo Nordisk downgraded to Hold from Buy at HSBCNovo Nordisk downgraded to Hold from Buy at HSBC

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

11/24/25

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

kr540

Buy

130.70%

Upside

Reiterated

11/04/25

Bernstein Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+5.41%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +5.41% per trade.

1 Year

Florent CespedesBernstein

Success Rate

3/7 ratings generated profit

Average Return

-14.76%

reiterated a buy rating 4 months ago

Copying Florent Cespedes's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -14.76% per trade.

2 Years

xxx

Success Rate

3/7 ratings generated profit

Average Return

-19.73%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -19.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QIU has received 27 Buy Ratings, 28 Hold Ratings, and 4 Sell Ratings. 0QIU average Analyst price target in the past 3 months is 300.92.

Each month's total comprises the sum of three months' worth of ratings.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr5.86 with a range of kr4.91 to kr9.84. The previous quarter’s EPS was kr6.04. 0QIU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr73.21B with a range of kr67.11B to kr94.38B. The previous quarter’s sales results were kr79.14B. 0QIU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 300.92.

What is GB:0QIU’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 28.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold, which is based on 1 buy ratings, 10 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 300.92. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr380.00 ,and the lowest forecast is kr250.00. The average share price target represents 28.56% Increase from the current price of kr234.07.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (0QIU) Share Forecast & Price Target

0QIU Analyst Ratings

0QIU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

0QIU Analyst Recommendation Trends

0QIU Financial Forecast

0QIU Earnings Forecast

0QIU Sales Forecast

0QIU Stock Forecast FAQ

Detailed List of Analyst Forecasts